Gavocabtagene autoleucel

CAMBRIDGE, Mass., Feb. 1, 2024 /PRNewswire/ -- Myeloid Therapeutics, Inc. ("Myeloid"), a clinical stage oncology company, has appointed Robert Hofmeister, Ph.D., as Chief Scientific Officer (CSO). An expert in immuno-oncology, gene and cell therapy, Dr. Hofmeister brings more than 25 years of scientific leadership experience and a track record of drug discovery and early development. "As Myeloid advances our novel pipeline of programs, I am thrilled to welcome Dr. Hofmeister as our new Chief Scientific Officer. His successful track record leading drug discovery teams, which contributed to the approval of two drugs by the FDA, will be instrumental in building upon our achievements and navigating the promising opportunities ahead," said Daniel Getts, Ph.D., Myeloid CEO. Dr. Hofmeister's appointment comes at a crucial time when Myeloid has achieved numerous milestones, including a Phase 1 clinical study with MT-302 for patients with TROP2-expressing tumors. Notably, this study investigates the first in vivo mRNA CAR candidate to ever be dosed in patients. In the year ahead, the company is on track to advance its second in vivo CAR program to the clinic targeting GPC3-positive liver cancers. In addition to being a key member of the executive management team, Dr. Hofmeister will lead the expansion of Myeloid's cutting-edge RNA focused research and development efforts, aimed at designing novel therapeutics that target, deliver, and program immune cells to combat cancer and other deadly diseases. "I'm thrilled to work with Myeloid's world class team and cutting-edge in vivo engineering platform to revolutionize the treatment of cancer and autoimmune diseases, and make a difference in the lives of patients," Robert Hofmeister, Ph.D. "Myeloid's in vivo mRNA programming platform is positioned to dramatically change the future of cancer immunotherapy and the treatment of other devastating diseases." Before joining Myeloid, Dr. Hofmeister was the CSO at Resonance Medicine where he drove the development of their discovery platform for therapeutic proteases. Previously, he served as CSO at TCR2 Therapeutics where he started as employee number one and was instrumental in building and leading the R&D function, driving the development of their proprietary TRuC®-T cell platform from concept to first cleared IND (TC-210 program) and successfully contributed to taking the company public as well as securing multi-million dollar rounds of fundraising. Dr. Hofmeister also held various roles at EMD Serono where he was involved in the development of now approved Bavencio (avelumab) and building the company's immuno-oncology platform. He started his biotech career at Micromet AG, now Amgen Research Munich, where he helped shape the development of Blincyto (blinatumomab), the first FDA-approved bispecific antibody for the treatment of refractory ALL. Dr. Hofmeister received his Ph.D. from the University of Regensburg in Germany, where he studied the signaling of the cytokine interleukin-1. He continued to work in the cytokine field as a postdoctoral fellow at the National Cancer Institute. About Myeloid Therapeutics Myeloid Therapeutics is a clinical stage oncology company developing novel therapies for cancer. Integrating the fields of mRNA-based therapeutics, immunology, and cancer biology, the Company's proprietary platform provides clinical solutions for patients with solid tumors. Myeloid is headquartered in Cambridge, MA. For more information visit: . Media Contact: Jennifer Hanley Ridge Hill Group [email protected] Investor Contact Amy Conrad Juniper Point [email protected] SOURCE Myeloid Therapeutics, Inc.

Adaptimmune Therapeutics, Monte Rosa Therapeutics and Intellia Therapeutics are all throwing programs to the discard pile. Many hoped the end of 2023 would bring some solace for biotech after nearly two years of challenging market conditions. As the year nears its end, that relief remains largely out of reach, as cuts to both teams and pipelines continue to climb. Today, at least three more biotechs have tossed candidates into the ever-growing pile of discontinued programs. First up is Adaptimmune Therapeutics, a biotech terminating two programs dubbed Gavo-cel and TC-510. After a review of safety and efficacy data for both candidates, the T-cell therapy company didn’t “see a path forward” for further development of either programs, according to a third-quarter earnings release. Gavo-vel was a phase 2 autologous cell therapy that had an overall response rate (ORR) of 11% across patients with ovarian cancer or mesothelioma. Meanwhile, cell therapy TC-510 was tied to one partial response in mesothelioma out of five patients with varying cancers but a high incidence of cytokine release syndrome and pneumonitis. The blow comes after GSK paid Adaptimmune 30 million pounds ($37.3 million) to wipe its hands of two programs this spring. One of the programs was lete-cel, an asset Adaptimmune had at one point touted as its leading cell therapy. As the biotech awaits an FDA approval decision for its investigational therapy targeting MAGE-A4 in solid tumors, dubbed Afami-cel, discovery work will continue with Roche’s Genentech on two allogeneic programs.    The second biotech cutting programs is Monte Rosa Therapeutics, a Boston-based biotech with a molecular glue platform. In a move to prioritize resources, the company is discontinuing an early-stage sickle cell program. Not much is known beyond that, as little was publicly revealed about the discovery program. The company will focus on other programs, such as its clinical-stage GSPT1-directed candidate called MRT-2359 and work with Roche, who inked a deal last month for the use of Monte Rosa’s QuEEN platform to target cancer and neurological diseases previously considered out of reach. Last but not least is Intellia Therapeutics, a Cambridge, Mass.-based company using CRISPR-based tech to build in vivo and ex vivo therapies. The biotech is halting all further preclinical activities for NTLA-2003, an asset designed to treat a rare, inherited disorder called AATD-associated liver disease. Instead, Intellia intends to advance a different AATD research-stage program that uses the company’s DNA writing technology. Intellia, which reported earnings this morning, saw its stock tumble 12% from $28.45 at market open this morning to $25.03 at 11 a.m. ET.  Less than a month ago, Intellia received the FDA green light to study NTLA-2001, an in vivo CRISPR-based gene editing therapy in the U.S. The company worked with sites in Europe and New Zealand to study the therapy in a phase 1 trial and showed NTLA-2001 may safely reduce levels of misfolded TTR, a protein that drives the rare, life-threatening disease ATTR amyloidosis. The new FDA allowance positions the company to start a phase 3 trial of the Regeneron-partnered candidate by the end of the year. Editor's note: This article was updated at 9:30 a.m. ET Nov. 10 with revisions to information provided about lete-cel.